Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
Laerdal Global Health has developed a PEEP valve which has been tested and shown to provide reliable end-expiratory pressures in a manikin model, even with a high mask leak. Whether this PEEP valve provides reliable PEEP in vivo and whether this translates to clinical beneficial outcomes remains to be proven.
The aim is to study whether lung aeration can be improved by adding a device for positive end expiratory pressure (PEEP) to better distend the airways in neonates more than 28 weeks gestation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Neonates who need assisted bag/mask ventilation after birth due to failure to initiate breathing the first 60 seconds after birth.
- Exclusion Criteria:
- • Babies with major deformities not deemed to be viable.
- • Missing parental consent
About Helse Stavanger Hf
Helse Stavanger HF is a leading healthcare organization based in Norway, dedicated to providing high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, Helse Stavanger HF focuses on innovative therapeutic interventions across various medical fields, aiming to enhance patient care and outcomes. With a commitment to ethical research practices and collaboration with academic institutions, the organization plays a vital role in the development of new treatments and the improvement of healthcare standards in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Haydom, Manyara, Tanzania
Patients applied
Trial Officials
Hussein Kidanto, MD, PhD
Principal Investigator
Muhimibili National Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials